• Cat-intel
  • MedIntelliX
  • Consulting
  • Resources
  • About Us
  • News
  • Careers
  • Contact Us
  • Login

    • Immune Thrombocytopenia (ITP) Companies

    ID: MRFR/Pharma/5531-CR
    105 Pages
    Rahul Gotadki
    December 2018

    Immune thrombocytopenia (ITP) is a disorder characterized by a low platelet count, leading to an increased risk of bleeding. Treatment for ITP may involve medications, such as immunosuppressants or thrombopoietin receptor agonists, as well as other therapeutic approaches.

    Share:
    Download PDF ×

    We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

    Immune Thrombocytopenia (ITP) Market Research Report - Forecast till 2034 Infographic
    Summary Table of Contents Segmentation Infographic

    Top Industry Leaders in the Immune Thrombocytopenia (ITP) Market

    Immune Thrombocytopenia CompaniesLatest Immune Thrombocytopenia Companies Update



    • December 2022: Argenx SE, a multinational immunology corporation dedicated to enhancing the quality of life for individuals afflicted with severe autoimmune disorders, disclosed results from its Phase 3 ADVANCE trial. The ADVANCE study represents the initial phase of two registrational trials that aim to assess the safety, effectiveness, and tolerability of VYVGART® (efgartigimod alfa-fcab) in adult patients diagnosed with primary ITP. ADVANCE represents the second Phase 3 clinical trial in which VYVGART exhibited a substantial clinical advantage, thereby reinforcing the investigators' conviction regarding the extensive potential of this asset across various IgG-mediated autoimmune diseases with high need. Chronic ITP patients who received VYVGART demonstrated a sustained platelet response (17/78; 21.8%) in comparison to those who received a placebo (2/40; 5%), according to the study. Between weeks 19 and 24 of treatment, sustained platelet response was characterized as platelet counts of 50x109/L or higher at a minimum of four of the last six scheduled visits.




    • January 2023: Bruker Corporation announced the acquisition of ACQUIFER Imaging GmbH, a pioneer in big-data management solutions for high-content microscopy and bioimaging, in January 2023. This acquisition provides networking technology, secure storage, and high-performance on-premise processing that enhance Bruker's advanced fluorescence microscopy imaging products, including light-sheet and super-resolution microscopy products, which produce substantial amounts of data. The development of the ACQUIFER HIVE system was motivated by the need to manage the exponential growth of data generated by life science research. By integrating Bruker's light-sheet microscopy instrumentation with their fluorescence microscopy platforms, they are now capable of providing a comprehensive solution for the management of large data and advanced imaging.


    List of Immune Thrombocytopenia Key companies in the market


    • CSL Limited




    • Amgen Inc.




    • F.Hoffmann-La Roche Ltd.




    • Kyowa Hakko Kirin Co., Ltd




    • Rigel Pharmaceuticals, Inc.




    • Shionogi Inc.




    • Dova Pharmaceuticals




    • Novartis AG




    • Jiangsu Hengrui Pharmaceutical Co., Ltd.




    • Shire




    • Ligand Pharmaceuticals, Inc.